Kantonsspital Graubuenden

Running trials

• Recruiting

  Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07149649· Phase 2/3· Source

• Recruiting

  Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

  NCT07158489· Phase 2· Source

• Recruiting

  Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

  NCT07020065· Phase 2· Source

• Recruiting

  Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

  NCT07140900· Phase 1· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Source

• Recruiting

  Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

  NCT05815927· Phase 3· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Source

• Recruiting

  Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06401980· Phase 2· Source

• Recruiting

  Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

  NCT06598306· Phase 1· Source

• Active, not recruiting

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· Phase 3· Source

• Recruiting

  Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

  NCT06114108· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Source

• Active, not recruiting

  Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

  NCT04630730· Phase 2· Source

• Active, not recruiting

  Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

  NCT04472949· Phase 2· Source

• Active, not recruiting

  Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

  NCT04245514· Phase 2· Source

• Recruiting

  Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT04221542· Phase 1· Source

• Recruiting

  E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

  NCT03818503· Source

• Active, not recruiting

  1st Line Durvalumab in PS 2 NSCLC Patients

  NCT03620669· Phase 2· Source

• Active, not recruiting

  Prostate Cancer Biobank

  NCT04024475· Source

• Active, not recruiting

  Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

  NCT00268476· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Prostate cancer3 recruiting
• Childhood cancers1 recruiting
• Head and neck cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· Phase 1/2· Source

• Terminated

  Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

  NCT04629781· Phase 1· Source

• Completed

  SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

  NCT04480372· Phase 2· Source

• Completed

  Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

  NCT04362072· Phase 4· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Source

• Completed

  Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

  NCT02910557· Source

• Terminated

  ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

  NCT02933801· Phase 2· Source

• Completed

  Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

  NCT02572843· Phase 2· Source

• Withdrawn

  Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

  NCT02053311· Phase 3· Source

• Recruiting

  AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

  NCT02102165· Source

• Completed

  Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery

  NCT01272050· Phase 3· Source